⌕
Universe Pharmaceuticals · UPC · Nasdaq
Tenet 62 · Solid
Compare
$1.56+5.41%At closeTenet 62 · Solid
$1.56+0.08 (+5.41%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Universe Pharmaceuticals (UPC) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 45% below its peak, net margin −20.6%.
The four lines that matter · FY21–FY25
Revenue ($B)▼22.4%
17.9
FY21→FY25CAGR +339.2%/yr
Net income ($B)▲57.9%
−3.7
one-off year: see footnoteCAGR —
Free cash flow ($B)▲45.2%
−5.3
FY21→FY25CAGR —
Diluted EPS▲98.7%
−8.06
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+0.0%

455.9mn → 455.9mn diluted shares since FY25. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$266.8M

+28.1% YoY in FY25 · 1.5% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)17858.7Revenue−11557.6COGS6301.2Gross profit−671.8R&D−8545.3SG&A−2915.9Op income−756.1Tax & other−3672.1Net income

-21¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.

Margin trend · direction beats level Gross Operating Net
604530150%sector median net margin ~3%FY21FY25

Over this window: gross 52.8% → 35.3%. Net margin -20.6% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemFY25 †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
17,858.717,858.723,024.532,308.740.148.0▼22.4%+339.2%
Cost of revenue
11,557.611,557.616,952.621,993.618.322.7▼31.8%+375.2%
Gross profit
6,301.26,301.26,071.910,315.121.925.3▲3.8%+297.2%
Research & development
671.8671.83,031.14,858.57.65.5▼77.8%+233.0%
Selling, general & admin
8,545.38,545.311,060.69,422.721.36.3▼22.7%+507.6%
Total operating expenses
9,698.29,698.214,091.714,281.228.911.7▼31.2%+436.2%
Operating incomefeeds ROC rank
−2,915.9−2,915.9−8,019.8−3,966.1−7.013.6▲63.6%—
Other income, net
−756.1−756.1−100.8−361.3−0.10.1——
Pretax income
−3,672.1−3,672.1−8,120.6−4,327.4−7.113.7▲54.8%—
Income tax
0.00.0606.72,253.60.82.4——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−3,672.1−3,672.1−8,727.3−6,581.0−7.911.4▲57.9%—
Per share
Diluted EPSbuyback-sensitive
−8.06−8.06−626.96−1089.21−1309.11—▲98.7%—
Diluted shares (mn)
455.87455.8713.926.040.0121.75▲3174.9%+114.0%
Margins
Gross margin18th pct in Healthcare
35.3%35.3%26.4%31.9%54.5%52.8%▲8.9pp−17.5pp
Operating margin
−16.3%−16.3%−34.8%−12.3%−17.5%28.3%▲18.5pp−44.7pp
Net margin22nd pct in Healthcare
−20.6%−20.6%−37.9%−20.4%−19.7%23.7%▲17.3pp−44.2pp
† FY25 = fiscal 2025, through 2025-09-30; the trailing year is not available.FY21 effective tax rate was 17% vs a −7% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was −52% vs a −7% norm for this window, likely a one-time item; see the filing.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-01-29 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Universe Pharmaceuticals' revenue last fiscal year?

Universe Pharmaceuticals reported revenue of $17.9B in fiscal 2025, down 22.4% from fiscal 2024.

What was Universe Pharmaceuticals' net income?

Universe Pharmaceuticals reported net income of −$3.7B in fiscal 2025, a net margin of −20.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.